The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study-Reference-Cited by-同舟云学术

The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study

Published:2017-05-08 Issue:5 Volume:178 Page:739-746
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Cederleuf Henrik¹^ORCID,Bjerregård Pedersen Martin²,Jerkeman Mats¹,Relander Thomas¹,d'Amore Francesco²,Ellin Fredrik¹³^ORCID

Affiliation:

1. Oncology and Pathology; Department of Clinical Sciences; Lund University; Lund Sweden

2. Department of Haematology; Aarhus University Hospital; Aarhus Denmark

3. Department of Internal Medicine; Kalmar County Hospital; Kalmar Sweden

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14740/fullpdf

Reference26 articles.

1. A systematic review and meta-analysis of front-line anthracycline-based chemotherapy regimens for peripheral T-cell lymphoma;Abouyabis;ISRN Hematology,2011

2. Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01;d'Amore;Journal of Clinical Oncology,2012

3. The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications;Campo;Blood,2011

4. De Nully Brown , P. Jörgensen , J. Munksgaard , L. Amdi Petersen , B. Pedersen , M. Jensen , P. Klausen , T. 2012 Annual report of the Danish Lymphoma Group (2011) http://www.lymphoma.dk/wp-content/uploads/2016/11/Aarsrapport_2011_ver_1_3.pdf

5. Real-world data on prognostic factors and treatment in peripheral T-cell lymphomas: a study from the Swedish Lymphoma Registry;Ellin;Blood,2014

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Discovery and efficacy study of an ALK inhibitor AMX6001 in anaplastic large cell lymphoma Karpas299 mice models;European Journal of Medicinal Chemistry Reports;2024-12

2. Brentuximab vedotin plus cyclophosphamide, doxorubicin, etoposide, and prednisone followed by brentuximab vedotin consolidation in CD30-positive peripheral T-cell lymphomas: a multicentre, single-arm, phase 2 study;The Lancet Haematology;2024-09

3. Etoposide addition and brentuximab vedotin consolidation in first-line treatment of CD30-positive peripheral T-cell lymphoma: can we improve BV–CHP?;The Lancet Haematology;2024-09

4. How I treat peripheral T-cell lymphomas;Russian journal of hematology and transfusiology;2024-03-19

5. Aggressive T‐cell lymphomas: 2024: Updates on diagnosis, risk stratification, and management;American Journal of Hematology;2024-02-02